Modified Peptides for Protease Detection in Extracellular Vesicles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and monitoring diseases, particularly viral infections and cancers, lack sensitivity and specificity, especially for latent reservoirs and residual tumor activity, due to low levels of shed antigens in peripheral fluids.
Innovation Solution
A method involving the measurement of enzymatic activity of disease-associated proteases in extracellular vesicles using modified peptides that enable Forster resonance energy transfer (FRET) and membrane translocation, allowing for sensitive detection without disrupting the vesicles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect disease antigens in peripheral fluids, then the detection process is simple, but the sensitivity is insufficient due to low levels of shed antigens
Solution Approach 1:
The patent uses modified peptide substrates as intermediaries that specifically bind to disease-associated proteases. These peptides are engineered with FRET markers and membrane translocation capabilities, serving as mediators between the protease target and the detection system, thereby amplifying the detectable signal from low-abundance antigens
Solution Approach 2:
The invention changes the detection parameter from direct antigen detection to enzymatic activity measurement. By detecting the proteolytic activity of disease-associated proteases through FRET signal changes, the method achieves higher sensitivity since enzyme activity can be amplified and measured more readily than low-concentration antigens
2Measurement precision
If protease activity is measured in extracellular vesicles without disruption, then the detection sensitivity is high, but the method complexity increases due to specialized peptide design requirements
Solution Approach 1:
The patent merges multiple functions into a single modified peptide substrate: FRET signaling capability, membrane translocation ability, and protease specificity. This consolidation allows the peptide to penetrate intact extracellular vesicles and detect protease activity internally, achieving high sensitivity without requiring vesicle disruption or multiple separate reagents
Solution Approach 2:
The invention replaces mechanical/physical vesicle disruption methods with a biochemical approach using membrane-translocating peptides. Instead of breaking open vesicles through centrifugation or lysis, the modified peptides naturally penetrate the vesicle membrane, substituting complex mechanical separation and lysis procedures with a simpler biochemical detection method
3Reliability
If ADAM-protease activity is used as a surrogate marker, then disease burden and activity can be monitored, but the reliability depends on the specificity of protease-disease association
Solution Approach 1:
The patent applies local quality by designing protease-specific peptide substrates that recognize unique cleavage sites of disease-associated ADAM proteases. Each peptide is tailored to match the specific substrate specificity of the target protease, ensuring that the measured activity reflects the presence and burden of the specific disease rather than general proteolytic activity
Solution Approach 2:
The invention implements feedback through FRET-based real-time monitoring of protease activity. The FRET signal provides immediate feedback on protease enzymatic activity, allowing dynamic monitoring of disease burden and treatment response. This continuous feedback mechanism enhances reliability by enabling longitudinal assessment of disease progression and therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a highly sensitive method for detecting diseases, including latent viral reservoirs and tumor activity, with ADAM-protease activity serving as a marker, enabling detection even in patients under antiviral treatment and before conventional imaging techniques can detect tumors.
Implementation Method 1
measurement of enzymatic activity of disease-associated proteases in extracellular vesicles using modified peptides that enable Forster resonance energy transfer (FRET)
Implementation Method 2
modified peptides that enable Forster resonance energy transfer (FRET) and membrane translocation, allowing for sensitive detection without disrupting the vesicles
Data Source
AI summary
The present invention relates to a method for in vitro detection and/or monitoring of a disease in a sample, based on measurement of enzymatic activity of proteases activated and secreted upon disease development, to modified peptides used for the enzymatic detection of the proteases, the use of the peptides, a kit comprising such peptides and the use of ADAM-protease activity as a surrogate marker for disease burden and activity in infectious, inflammatory, and malignant diseases, such as HIV infection and melanoma.